The generative AI market in drug discovery is expanding rapidly, expected to grow from $0.33 billion in 2026 to $0.86 billion by 2030 with a 27% CAGR. Growth is fueled by rising drug development costs, advances in AI technologies like deep learning, and increased biological data availability. Key trends include AI-driven molecule generation and faster early-stage drug development, with major companies like Bayer, NVIDIA, and Merck leading innovations. The market is also benefiting from more clinical trials and strategic acquisitions, indicating a transformative impact on pharmaceutical R&D and personalized medicine.
The global silicon interposer market, valued at $4 billion in 2025, is projected to grow to $14.04 billion by 2035 with a CAGR of 13.38%. Growth is fueled by rising adoption of AI, chiplet architectures, and advanced semiconductor packaging technolog...
Nvidia's stock declined as Meta, one of its major customers, shifts more resources to develop in-house artificial intelligence processors. This move signals increased competition for Nvidia in the AI chip market, potentially impacting its future sale...
The global Edge AI semiconductor market, valued at $25.36 billion in 2025, is projected to grow to $151.30 billion by 2035 with a CAGR of 19.57%. Growth is fueled by increasing use of AI processors in consumer electronics, automotive, healthcare, and...
The Roundhill NVDA WeeklyPay ETF (NVDW) provides investors a leveraged, quasi-synthetic position in Nvidia with a highly variable income stream. Although it shows a trailing yield near 60%, the actual yield on cost is closer to 40%, and weekly payout...
The inaugural Juneteenth Exchange summit in Rancho Cordova gathered over 150 leaders from business, technology, and investment sectors to discuss innovation, economic opportunity, and inclusive leadership. The event highlighted the city's growing app...
